α7 nicotinic acetylcholine receptors are necessary for basal forebrain activation to increase expression of the nerve growth factor receptor TrkA.
Alzheimer’s
acetylcholine
deep brain stimulation
neurotrophin
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
03 Mar 2024
03 Mar 2024
Historique:
pubmed:
11
3
2024
medline:
11
3
2024
entrez:
11
3
2024
Statut:
epublish
Résumé
Activation of the basal forebrain leads to increases in the expression of the nerve growth factor receptor, Tropomyosin receptor kinase A (TrkA) and decreases in expression of the beta amyloid cleavage enzyme 1 (BACE1) in the cerebral cortex of both sexes of 5xFAD mice. The studies described in this report were designed to determine if these changes were dependent on acetylcholine receptors. Mice were stimulated unilaterally in the basal forebrain for two weeks. Animals were administered a cholinergic antagonist, or saline, 30 minutes prior to stimulation. Animals administered saline exhibited significant increases in TrkA expression and decreases in BACE1 in the stimulated hemisphere relative to the unstimulated. While both nonselective nicotinic and muscarinic acetylcholine receptor blockade attenuated the BACE1 decline, only the nicotinic receptor antagonism blocked the TrkA increase. Next, we applied selective nicotinic antagonists, and the α7 antagonist blocked the TrkA increases, but the α4β2 antagonist did not. BACE1 declines were not blocked by either intervention. Mice with a loxP conditional knockout of the gene for the α7 nicotinic receptor were also employed in these studies. Animals were either stimulated bilaterally for two weeks, or left unstimulated. With or without stimulation, the expression of TrkA receptors was lower in the cortical region with the α7 nicotinic receptor knockdown. We thus conclude that α7 nicotinic receptor activation is necessary for normal expression of TrkA and increases caused by basal forebrain activation, while BACE1 declines caused by stimulation have dependency on a broader array of receptor subtypes.
Identifiants
pubmed: 38463995
doi: 10.1101/2024.03.01.582932
pmc: PMC10925259
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIMH NIH HHS
ID : R21 MH121959
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG060754
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH120876
Pays : United States
Organisme : BLRD VA
ID : I01 BX004758
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS083858
Pays : United States
Organisme : NINDS NIH HHS
ID : R56 NS083858
Pays : United States
Références
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1267-72
pubmed: 19147841
J Physiol Sci. 2007 Dec;57(6):383-7
pubmed: 18028583
Trends Pharmacol Sci. 2018 Apr;39(4):354-366
pubmed: 29428175
PLoS One. 2013 Aug 30;8(8):e72457
pubmed: 24023619
Curr Drug Targets. 2012 May;13(5):613-22
pubmed: 22300028
J Neurosci. 2010 Nov 17;30(46):15608-15
pubmed: 21084616
Ann Neurol. 2004 Oct;56(4):520-31
pubmed: 15455399
Curr Alzheimer Res. 2007 Sep;4(4):351-8
pubmed: 17908036
J Neurosci. 2010 Feb 17;30(7):2442-53
pubmed: 20164328
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4067-72
pubmed: 10097164
Nat Commun. 2016 Nov 04;7:13249
pubmed: 27811848
J Neurosci. 1997 Jul 15;17(14):5445-54
pubmed: 9204927
Neuroscience. 2005;130(4):997-1012
pubmed: 15652996
Front Behav Neurosci. 2013 Aug 08;7:102
pubmed: 23964215
Dement Geriatr Cogn Disord. 1998 Sep-Oct;9(5):246-57
pubmed: 9701676
Neuropharmacology. 2013 Apr;67:201-12
pubmed: 23168113
Cereb Cortex. 2023 Jun 8;33(12):7627-7641
pubmed: 36939283
Nat Neurosci. 2005 Aug;8(8):1069-77
pubmed: 16025106
IEEE Trans Biomed Eng. 1990 Nov;37(11):1118-20
pubmed: 2276759
Brain Res. 1976 Jun 4;109(1):152-7
pubmed: 819100
J Neurosci. 2002 Sep 15;22(18):7903-12
pubmed: 12223543
Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6735-40
pubmed: 16618925
Science. 1982 Mar 5;215(4537):1237-9
pubmed: 7058341
J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86
pubmed: 20504913
IEEE Trans Biomed Eng. 1992 Apr;39(4):424-6
pubmed: 1592409
J Neurosci. 2000 Jan 1;20(1):66-75
pubmed: 10627582
J Mol Neurosci. 2010 Jan;40(1-2):230-5
pubmed: 19680822
Brain. 1976 Sep;99(3):459-96
pubmed: 11871
Front Cell Neurosci. 2014 Aug 07;8:220
pubmed: 25147503
Neurobiol Dis. 2017 Dec;108:307-323
pubmed: 28865749
Science. 2001 Nov 30;294(5548):1945-8
pubmed: 11729324
J Comp Neurol. 2000 Nov 6;427(1):19-30
pubmed: 11042589
Behav Brain Res. 2022 Feb 15;419:113709
pubmed: 34890598
Nature. 1991 Mar 14;350(6314):158-60
pubmed: 1706478
J Neurochem. 2002 Aug;82(4):809-18
pubmed: 12358786
Trends Pharmacol Sci. 2014 Jul;35(7):338-48
pubmed: 24962069
Neurosci Res. 2009 Feb;63(2):122-8
pubmed: 19059440
Neurobiol Aging. 2002 Mar-Apr;23(2):213-23
pubmed: 11804705
J Neurosci Res. 2004 Jul 15;77(2):250-7
pubmed: 15211591
J Med Eng Technol. 2000 May-Jun;24(3):123-8
pubmed: 11036579
J Neurophysiol. 2009 Apr;101(4):1941-60
pubmed: 19164104
Neurosci Lett. 2012 May 2;515(2):125-30
pubmed: 22450048
Ann N Y Acad Sci. 1998 Jun 19;845:32-45
pubmed: 9668341
Clin Neurophysiol. 2004 Mar;115(3):589-95
pubmed: 15036055
J Neurosci. 1993 Apr;13(4):1719-29
pubmed: 8463847
Lancet. 1976 Dec 25;2(8000):1403
pubmed: 63862
J Neurochem. 2000 Sep;75(3):1155-61
pubmed: 10936198
J Neurosci Res. 2001 Nov 15;66(4):565-72
pubmed: 11746376
Antioxid Redox Signal. 2013 Oct 10;19(11):1135-48
pubmed: 23311871
Curr Opin Neurobiol. 2002 Jun;12(3):268-74
pubmed: 12049932
Mol Psychiatry. 2018 May;23(5):1094-1112
pubmed: 29483673
Life Sci. 1994;55(5):PL91-8
pubmed: 8035645
J Neurophysiol. 1968 Sep;31(5):659-69
pubmed: 5711137
Life Sci. 2002 Feb 15;70(13):1543-54
pubmed: 11895105
J Biol Chem. 1995 Dec 22;270(51):30701-8
pubmed: 8530509